end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableAndAccruedLiabilitiesCurrent,AccountsPayableAndOtherAccruedLiabilitiesCurrent,AccruedProfessionalFeesCurrent,AdditionalPaidInCapital,AllocatedShareBasedCompensationExpense,Assets,Cash,CashAndCashEquivalentsAtCarryingValue,CashAndCashEquivalentsPeriodIncreaseDecrease,CashFDICInsuredAmount,CommonStockCapitalSharesReservedForFutureIssuance,CommonStockParOrStatedValuePerShare,CommonStockSharesAuthorized,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockValue,CurrentFederalStateAndLocalTaxExpenseBenefit,DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount,DeferredCompensationShareBasedArrangementsLiabilityCurrent,EarningsPerShareBasic,EarningsPerShareBasicAndDiluted,EarningsPerShareDiluted,EffectiveIncomeTaxRateContinuingOperations,EmployeeRelatedLiabilitiesCurrent,EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions,GeneralAndAdministrativeExpense,IncomeTaxExpenseBenefit,IncreaseDecreaseInAccountsPayableAndAccruedLiabilities,IncreaseDecreaseInPrepaidExpense,IssuanceOfStockAndWarrantsForServicesOrClaims,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,OperatingExpenses,PaymentsOfStockIssuanceCosts,PrepaidExpenseCurrent,ProceedsFromIssuanceInitialPublicOffering,ProceedsFromIssuanceOfPrivatePlacement,ProfitLoss,RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,SellingGeneralAndAdministrativeExpense,ShareBasedCompensation,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares,SharesIssuedPricePerShare,StockGrantedDuringPeriodValueSharebasedCompensation,StockholdersEquityNoteStockSplitConversionRatio1,StockIssuedDuringPeriodSharesConversionOfUnits,StockIssuedDuringPeriodSharesNewIssues,StockIssuedDuringPeriodValueConversionOfUnits,StockIssuedDuringPeriodValueIssuedForServices,StockIssuedDuringPeriodValueNewIssues,WeightedAverageNumberOfDilutedSharesOutstanding,WeightedAverageNumberOfShareOutstandingBasicAndDiluted,WeightedAverageNumberOfSharesOutstandingBasic,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,DeferredTaxAssetsGross,DeferredTaxAssetsInProcessResearchAndDevelopment,DeferredTaxAssetsOperatingLossCarryforwards,DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost,DeferredTaxAssetsValuationAllowance,EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate,EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance,EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment,EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes,OperatingLossCarryforwards
2021-06-30,2021-08-13,10-Q,"Acurx Pharmaceuticals,Â Inc.",ACXP,CIK0001736243,USD,1918639.0,97005.0,1750146.0,34790591.0,563889.0,17440145.0,17095596.0,17095596.0,,17100000.0,,0.001,200000000.0,9916208.0,9916208.0,9916.0,,,0.0,,-0.57,,,20242.0,2180640.0,3975488.0,,,,,1918639.0,17440145.0,1918639.0,,,-4004059.0,4070562.0,,344549.0,,,,0.0,95074.0,-19279001.0,,,,0.0108,0.93,807500.0,4.75,0.0,462000.0,6.26,6.26,345500.0,,2219774.0,,,,0.0,37500.0,14797132.0,,6968341.0,,,,,,,,,,,,
2021-09-30,2021-11-12,10-Q,"Acurx Pharmaceuticals,Â Inc.",ACXP,CIK0001736243,USD,712437.0,12142.0,133194.0,38188287.0,0.0,14989628.0,14459046.0,14459046.0,,14500000.0,,0.001,200000000.0,10126903.0,10126903.0,10127.0,,,0.0,-0.46,,-0.46,,252117.0,7399003.0,3515250.0,,,,,712437.0,14989628.0,712437.0,,,-4642222.0,4642222.0,,530582.0,,,,7500.0,1126972.0,-23921223.0,,,,,,2357500.0,,0.0,1569333.0,6.2,6.21,788167.0,,2070637.0,,,,,1327270.0,,10116403.0,,10116403.0,,,,,,,,,,,
2021-12-31,2022-03-16,10-K,"Acurx Pharmaceuticals,Â Inc.",ACXP,CIK0001736243,USD,843909.0,63374.0,43102.0,38948334.0,755556.0,13254150.0,12958846.0,,9783435.0,13000000.0,,0.001,200000000.0,10215792.0,10215792.0,10216.0,0.0,,,-1.49,,-1.49,0.0,508343.0,6726367.0,10784023.0,,387978.0,246695.0,916765.0,843909.0,13254150.0,843909.0,14797132.0,-5013697.0,-12747697.0,12814200.0,2452868.0,295304.0,14797132.0,,-12747697.0,7500.0,2030177.0,-26548309.0,208270.0,5154714.0,2.14,0.0109,0.93,2357500.0,4.72,0.0,1426667.0,,4.72,930833.0,,5154714.0,,,,,1587741.0,14797132.0,8535873.0,,8535873.0,12958846.0,2850251.0,105881.0,1594650.0,1149720.0,2850251.0,0.21,-0.271,0.01,0.051,6100000.0
